Lobe Sciences Ltd. (CSE: LOBE)(OTCQB: LOBEF)(Frankfurt: LOBE.F), a clinical-stage biopharmaceutical company, announced on October 8, 2026 its intention to strengthen its capital markets presence through three proposed initiatives: engaging an independent market maker, launching an expanded investor and public relations programme, and appointing a U.S. capital markets professional to its Board of Directors. The announcement coincides with the company's stated progress toward a U.S. Investigational New Drug (IND) application for its lead asset, L-130 (Conjugated Psilocin®), anticipated in the first quarter of 2027. Investors may be watching closely as the company works to broaden its investment audience ahead of a key regulatory milestone.

Key Points

  • Lobe Sciences Ltd. (CSE: LOBE)(OTCQB: LOBEF)(Frankfurt: LOBE.F) — clinical-stage biopharmaceutical company
  • Company intends to engage an independent market maker, expand investor relations, and appoint a new board director with U.S. capital markets experience
  • U.S. IND submission for L-130 (Conjugated Psilocin®) targeted for Q1 2027; S-100 Phase 3 development expected to begin mid-2027
  • No service providers have been selected and no terms have been agreed upon for any of the proposed initiatives

Proposed Market-Making and Liquidity Support for LOBE Shares

Lobe Sciences stated its intention to engage an independent market maker in compliance with applicable securities laws and Canadian Securities Exchange policies. The company noted the engagement is intended to support liquidity and the orderly trading of its shares, and would not be designed to influence the market price. However, the company has not yet selected a service provider or agreed to any terms. The immediate share price impact was not clear from available public information. Any finalised engagement would be announced separately, including the identity of the party and material compensation terms, as required under applicable regulations.

Expanded Investor Relations Programme Targeting Canada and the United States

The company plans to launch a coordinated investor relations and public relations campaign covering digital communications, media outreach, investor conferences, and meetings with investment professionals across Canada and the United States. The programme is intended to communicate Lobe's business model and highlight progress on its two key development programmes: L-130 (Conjugated Psilocin®), being advanced through subsidiary Cynaptec Pharmaceuticals, and S-100 for sickle cell disease, developed through Applied Lipid Technologies. The company confirmed it has not yet selected a provider or agreed on scope, term, or compensation, and that any engagement will be subject to CSE acceptance.

L-130 Development Progress and Planned U.S. IND Submission

Lobe Sciences reported that development of L-130, a patented new chemical entity described as psilocin mucate, continues in accordance with previously disclosed plans. The company is targeting a U.S. IND submission to the Food and Drug Administration in the first quarter of 2027, with development addressing cluster headache as well as PTSD, substance use disorder, and generalized anxiety disorder, among other conditions. S-100 for sickle cell disease is also progressing, with Phase 3 development anticipated to begin in mid-2027. The company stated it expects to provide further details on development milestones in the near term.